Regeneron Pharmaceuticals (REGN) Non Operating Income (2009 - 2026)

Regeneron Pharmaceuticals' Non Operating Income history runs 18 years deep, the most recent figure standing at $201.2 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 37.52% year-over-year to $201.2 million; the TTM figure through Mar 2026 stood at $1.6 billion (up 39.0% YoY), while the FY2025 annual figure was $1.7 billion, up 114.98% from the prior year.
• Non Operating Income was $201.2 million for Q1 2026 at Regeneron Pharmaceuticals, up from $176.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $736.5 million in Q3 2025 to a low of -$197.4 million in Q1 2022.
• Historically, Non Operating Income has averaged $172.4 million across 5 years, with a median of $176.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Non Operating Income sank 227.44% in 2022, then soared 156850.0% in 2024.
• A 5-year view of Non Operating Income shows it stood at $237.3 million in 2022, then sank by 49.43% to $120.0 million in 2023, then sank by 164.0% to -$76.8 million in 2024, then soared by 329.17% to $176.0 million in 2025, then climbed by 14.32% to $201.2 million in 2026.
• The last three Non Operating Income figures came in at $201.2 million (Q1 2026), $176.0 million (Q4 2025), and $736.5 million (Q3 2025), per Business Quant data.